| http://www.w3.org/ns/prov#value | - BEVERLY, MA--(Marketwire - Oct 8, 2012) - Cellceutix Corporation (OTCBB: CTIX) (the Company), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, reports today that it has been advised that the clinical trials for the Company's novel anti-cancer drug candidate, Kevetrin
|
